-
Additional file 3 of Risk factors for the critical illness in SARS-CoV-2 infe...
Additional file 3: Supplementary Table S3. Laboratory findings of all critically ill patients on admission and before discharge. -
dedup_wf_001--466c5e6b71041026dbcedc758527feaf
Table S1. One-year incidence rates of subtypes of cancer per 1,000 person-years according to age group. Table S2A. Incidence rate ratios of cancer associated with an MI adjusted... -
Additional file 1 of Efficacy of a high-dose proton pump inhibitor in patient...
Additional file 1. Supplementary Table S1. Time-Course Changes of Reflux Symptom Scores between the Two Groups. Supplementary Table S2. Frequency Distribution of Atypical... -
Additional file 2 of The burden of healthcare-associated infection in Ethiopi...
Additional file 2. Studies to estimate HCAI. -
Additional file 4 of Risk factors for the critical illness in SARS-CoV-2 infe...
Additional file 4: Supplementary Table S4. Laboratory findings of critically ill patients on admission, different hospitals. -
MOESM15 of Effect of tetracycline treatment regimens on antibiotic resistance...
Additional file 15: Figure S15. Prevalence of tet(A), tet(B), sulI and sulII of all batches chronologically on farm 3. Top graph is values prior to treatment (T1), middle graph... -
Generalization of the time-to-event continual reassessment method to bivariat...
This article considers the problem of designing Phase I-II clinical trials with delayed toxicity and efficacy outcomes. The proposed design is motivated by a Phase I-II study... -
Additional file 3: of Distribution of influenza virus types by age using case...
Table S2. Summary Relative Illness Ratio (sRIR), 95% confidence intervals (95% CI) across age groups and influenza viruses by categories of country ageing index. The Global... -
Additional file 1 of Risk factors for the critical illness in SARS-CoV-2 infe...
Additional file 1: Supplementary Table S1. Reference value of variables and their potential confounders adjusted in multivariable logistic regression. -
Additional file 2: of Efficacy and safety of lasmiditan in patients using con...
Table S2. Treatment-emergent adverse events occurred at similar rates in patients using and not using migraine preventive treatments for all doses of lasmiditan. (DOCX 16 kb) -
Additional file 1: Tables of Estimating the morbidity and mortality associate...
a, b, c. Table a, table b, table c have been added as supplementary material. Table a presents the methodology, parameters and main results of 3 studies estimating the morbidity... -
Additional file 5 of Risk factors for the critical illness in SARS-CoV-2 infe...
Additional file 5: Supplementary Table S5. Imaging features on admission, different hospitals. -
MOESM14 of Effect of tetracycline treatment regimens on antibiotic resistance...
Additional file 14: Figure S14. Prevalence of tet(A), tet(B), sulI and sulII of all batches chronologically on farm 2. Top graph is values prior to treatment (T1), middle graph... -
dedup_wf_001--d6c72c7e0cd76c1ffbce9fda9e16b0da
Additional file 3 Comparisons between real data and model predictions obtained by method 2. -
Additional file 4 of Declining trend in HIV new infections in Guangxi, China:...
Additional file 4 Yearly new infections, undiagnosed prevalence, and diagnosis probabilities from 1990 to 2017 (estimated by method 1).
